share_log
Breakings ·  Sep 5 19:00
Study Confirms the Ability of Castle Biosciences' Decisiondx®-Scc Test to Predict Likelihood of Benefit From Adjuvant Radiation Therapy in Patients With High-Risk Cutaneous Squamous Cell Carcinoma
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment